Grant: Engage Grants Program
University of Toronto
$24,985.00
Peptide functionalized bone implant coatings for improved osteointegration
FY 2011-12
Summary
Canada's ageing population fuels the need for effective bone replacement due to fractures or tumors. The
global orthopedic market was valued at $25 billion in 2006. Orthopedic procedures typically require costly
operating rooms, consume specialists' time, and have long recovery periods. Unfortunately, many orthopedic
procedures fail due to infections contracted at the repair site. Thus, new engineering advances are required to
develop improved bone contacting materials. Covalon has developed proprietary bone implant material
coatings that improve biocompatibility, prevent infection and enhance lubrication. However, poor integration
of the bone implant with the underlying bone, regardless of the presence of coating, is the most common cause
of graft failure and a common cause of complications often requiring reoperation. Dr. Radisic and colleagues
identified a novel peptide sequence, QHREDGS, that promotes survival of many cell types including
cardiomyocytes, endothelial cells and human stem cells. Covalon started a new collaboration with Dr. Radisic
that aims to incorporate QHREDGS peptide into Covalon's polyacrylate bone implant coatings, for enhanced
osteogenesis. Dr. Radisic and colleagues will develop methods for covalent grafting of QHREDGS peptide into
the coatings. They will also assess viability and phenotypic responses of osteoblasts upon in vitro culture on
QHREDGS peptide modified bone implant coatings. Further research will be performed under other funding
programs (e.g. NSERC CRD). Ultimately, this line of research will result in a new product for Covalon: bone
implant coating that prevents microbial infection and enhances osteogenesis.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
417439-2011
Name nom
Radisic, Milica
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
24985
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Peptide functionalized bone implant coatings for improved osteointegration
Keyword
NSERC
Application summary
Canada's ageing population fuels the need for effective bone replacement due to fractures or tumors. The
global orthopedic market was valued at $25 billion in 2006. Orthopedic procedures typically require costly
operating rooms, consume specialists' time, and have long recovery periods. Unfortunately, many orthopedic
procedures fail due to infections contracted at the repair site. Thus, new engineering advances are required to
develop improved bone contacting materials. Covalon has developed proprietary bone implant material
coatings that improve biocompatibility, prevent infection and enhance lubrication. However, poor integration
of the bone implant with the underlying bone, regardless of the presence of coating, is the most common cause
of graft failure and a common cause of complications often requiring reoperation. Dr. Radisic and colleagues
identified a novel peptide sequence, QHREDGS, that promotes survival of many cell types including
cardiomyocytes, endothelial cells and human stem cells. Covalon started a new collaboration with Dr. Radisic
that aims to incorporate QHREDGS peptide into Covalon's polyacrylate bone implant coatings, for enhanced
osteogenesis. Dr. Radisic and colleagues will develop methods for covalent grafting of QHREDGS peptide into
the coatings. They will also assess viability and phenotypic responses of osteoblasts upon in vitro culture on
QHREDGS peptide modified bone implant coatings. Further research will be performed under other funding
programs (e.g. NSERC CRD). Ultimately, this line of research will result in a new product for Covalon: bone
implant coating that prevents microbial infection and enhances osteogenesis.